A protein kinase inhibitor called a mammalian target of rapamycin (mTOR) inhibitor used for the treatment of advanced kidney cancer that has come back during or after treatment (second line treatment). mTOR inhibitors act in a similar manner to TKIs by interfering with the signalling pathway that controls tumour cell growth and growth of new blood vessels (angiogenesis) into a solid tumour, thereby starving the tumour of nutrients and oxygen needed for growth. Everolimus is a type of angiogenesis inhibitor. Everolimus is the chemical (or generic) name of the drug, while Afinitor is the brand (or trade) name under which the drug is licensed and sold.

Share this Post!